Homart Pharmaceuticals Pty Ltd v Careline Australia Pty Ltd

In the case of Homart Pharmaceuticals Pty Ltd v Careline Australia Pty Ltd, the Full Court of the Federal Court of Australia addressed an appeal concerning the similarity of packaging and presentation of cosmetic products sold by the parties. The primary judge had ruled in favour of Careline, finding that Homart's packaging and get-up for its bio-placenta products were misleadingly similar to Careline's products. The appeal raised issues about whether the primary judge erred in his assessment of the similarity, the significance of the absence of evidence of consumer confusion, and the proper application of the principle in Australian Woollen Mills Limited v FS Walton & Co Limited.

The court found that the primary judge was entitled to assess Homart's intention by considering the whole of the evidence rather than solely the branding. The court also determined that the primary judge had overlooked some evidence regarding the reasons for Homart's change in packaging. However, the court held that these errors did not affect the overall conclusion that the products were strikingly similar. The absence of evidence of consumer confusion was noted but deemed of little weight by the primary judge, a conclusion the court found to be proper. The court further held that the principle in Australian Woollen Mills was correctly applied, and that there was no conflation of different product variants.

Ultimately, the appeal was dismissed. The court upheld the primary judge's finding that the products were strikingly similar, and that Homart's conduct was likely to mislead or deceive the public. The appellant was ordered to pay the respondents' costs of the appeal.